{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:07:49Z","timestamp":1777392469013,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"am","delay-in-days":357,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DA047347"],"award-info":[{"award-number":["R01DA047347"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR003017"],"award-info":[{"award-number":["UL1TR003017"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["T32MH013043"],"award-info":[{"award-number":["T32MH013043"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["1R18HS023258"],"award-info":[{"award-number":["1R18HS023258"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["R01HS026001"],"award-info":[{"award-number":["R01HS026001"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","award":["IHS-1409-23194"],"award-info":[{"award-number":["IHS-1409-23194"]}],"id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","jaacap.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jaac.2020.09.023","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T05:18:34Z","timestamp":1603171114000},"page":"877-886","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Trends in Antipsychotic Medication Use in Young Privately Insured Children"],"prefix":"10.1016","volume":"60","author":[{"given":"Greta A.","family":"Bushnell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Olfson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaac.2020.09.023_bib1","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1377\/hlthaff.2016.0064","article-title":"Rapid growth of antipsychotic prescriptions for children who are publicly insured has ceased, but concerns remain","volume":"35","author":"Crystal","year":"2016","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.jaac.2020.09.023_bib2","series-title":"Future Research Needs for First- and Second-Generation Antipsychotics for Children and Young Adults","author":"Christian","year":"2012"},{"key":"10.1016\/j.jaac.2020.09.023_bib3","series-title":"Off-Label Use of Atypical Antipsychotics: An Update","author":"Maglione","year":"2011"},{"key":"10.1016\/j.jaac.2020.09.023_bib4","series-title":"Atypical Antipsychotic Medications: Use in Pediatric Patients","year":"2015"},{"key":"10.1016\/j.jaac.2020.09.023_bib5","doi-asserted-by":"crossref","first-page":"w770","DOI":"10.1377\/hlthaff.28.5.w770","article-title":"Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges","volume":"28","author":"Crystal","year":"2009","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.jaac.2020.09.023_bib6","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/jamapsychiatry.2015.0500","article-title":"Treatment of young people with antipsychotic medications in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jaac.2020.09.023_bib7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1176\/appi.ps.201200081","article-title":"Antipsychotic use by medicaid-insured youths: impact of eligibility and psychiatric diagnosis across a decade","volume":"64","author":"Zito","year":"2013","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.jaac.2020.09.023_bib8","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archpedi.158.8.753","article-title":"New users of antipsychotic medications among children enrolled in TennCare","volume":"158","author":"Cooper","year":"2004","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.jaac.2020.09.023_bib9","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/070674371205701202","article-title":"A\u00a0review of pharmacoepidemiologic studies of antipsychotic use in children and adolescents","volume":"57","author":"Patten","year":"2012","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.jaac.2020.09.023_bib10","first-page":"13","article-title":"Trends in antipsychotic drug use by very young, privately insured children","volume":"49","author":"Olfson","year":"2010","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2020.09.023_bib11","series-title":"Choosing Wisely: Five Things Physicians and Patients Should Question","year":"2015"},{"key":"10.1016\/j.jaac.2020.09.023_bib12","author":"Findling"},{"issue":"5 Suppl","key":"10.1016\/j.jaac.2020.09.023_bib13","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.acap.2014.05.009","article-title":"Quality concerns in antipsychotic prescribing for youth: a review of treatment guidelines","volume":"14","author":"Kealey","year":"2014","journal-title":"Acad Pediatr"},{"key":"10.1016\/j.jaac.2020.09.023_bib14","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00787-006-0580-1","article-title":"Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials","volume":"16","author":"Jensen","year":"2007","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2020.09.023_bib15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/jamapsychiatry.2018.3421","article-title":"Association of antipsychotic treatment with risk of unexpected death among children and youths","volume":"76","author":"Ray","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jaac.2020.09.023_bib16","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/wps.20765","article-title":"Safety of 80 antidepressants, antipsychotics, anti-attention-deficit\/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects","volume":"19","author":"Solmi","year":"2020","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jaac.2020.09.023_bib17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapsychiatry.2015.2923","article-title":"Type 2 Diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis","volume":"73","author":"Galling","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jaac.2020.09.023_bib18","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1542\/peds.2011-2158","article-title":"Antipsychotics for children and young adults: a comparative effectiveness review","volume":"129","author":"Seida","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2020.09.023_bib19","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1001\/jama.2015.0763","article-title":"Medicaid prior authorization policies for pediatric use of antipsychotic medications","volume":"313","author":"Schmid","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jaac.2020.09.023_bib20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1001\/jamapsychiatry.2017.3493","article-title":"Pediatric use of antipsychotic medications before and after medicaid peer review implementation","volume":"75","author":"Zito","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jaac.2020.09.023_bib21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1176\/appi.ps.201700177","article-title":"The impact of a state medicaid peer-review authorization program on pediatric use of antipsychotic medications","volume":"69","author":"Pennap","year":"2018","journal-title":"Psychiatr Serv"},{"issue":"1","key":"10.1016\/j.jaac.2020.09.023_bib22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaac.2016.10.005","article-title":"Trends in antipsychotic prescribing in Medicaid-eligible youth","volume":"56","author":"Edelsohn","year":"2017","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2020.09.023_bib23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13034-017-0192-1","article-title":"A\u00a0multi-national comparison of antipsychotic drug use in children and adolescents, 2005-2012","volume":"11","author":"Kalverdijk","year":"2017","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"10.1016\/j.jaac.2020.09.023_bib24","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/pds.5032","article-title":"Spillover effects of state Medicaid antipsychotic prior authorization policies in US commercially insured youth","volume":"29","author":"Spence","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaac.2020.09.023_bib25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1001\/archpedi.159.4.362","article-title":"Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States","volume":"159","author":"Curtis","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.jaac.2020.09.023_bib26","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s11920-013-0426-8","article-title":"Use of antipsychotic medications in pediatric populations: what do the data say?","volume":"15","author":"Penfold","year":"2013","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.jaac.2020.09.023_bib28","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S2215-0366(18)30293-1","article-title":"Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases","volume":"5","author":"Raman","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jaac.2020.09.023_bib29","first-page":"686","article-title":"Impact of Maine's Medicaid drug formulary change on non-Medicaid markets: spillover effects of a restrictive drug formulary","volume":"9","author":"Wang","year":"2003","journal-title":"Am J Manag Care"},{"issue":"Spec No","key":"10.1016\/j.jaac.2020.09.023_bib30","first-page":"SP14","article-title":"Physicians' prescribing responses to a restricted formulary: the impact of Medicaid preferred drug lists in Illinois and Louisiana","volume":"11","author":"Virabhak","year":"2005","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jaac.2020.09.023_bib32","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jaac.2019.11.018","article-title":"Practice parameter for the assessment and treatment of psychiatric disorders in children and adolescents with intellectual disability (intellectual developmental disorder)","volume":"59","author":"Siegel","year":"2020","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2020.09.023_bib33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jaac.2013.10.013","article-title":"Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder","volume":"53","author":"Volkmar","year":"2014","journal-title":"J\u00a0American Acad Child Adolescent Psychiatry"},{"key":"10.1016\/j.jaac.2020.09.023_bib34","first-page":"CD008559","article-title":"Atypical antipsychotics for disruptive behaviour disorders in children and youths","volume":"8","author":"Loy","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaac.2020.09.023_bib35","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.cpr.2010.11.005","article-title":"Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations","volume":"31","author":"McKinney","year":"2011","journal-title":"Clin Psychol Rev"},{"key":"10.1016\/j.jaac.2020.09.023_bib36","doi-asserted-by":"crossref","first-page":"e1577","DOI":"10.1542\/peds.2010-1361","article-title":"Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing management","volume":"129","author":"Scotto Rosato","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2020.09.023_bib37","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1176\/appi.ps.201300391","article-title":"Concurrent use of stimulants and second-generation antipsychotics among children with ADHD enrolled in Medicaid","volume":"66","author":"Kamble","year":"2015","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.jaac.2020.09.023_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180355","article-title":"The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials","volume":"12","author":"Catala-Lopez","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jaac.2020.09.023_bib39","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-2528","article-title":"Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents","volume":"144","author":"Wolraich","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2020.09.023_bib40","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jaac.2013.11.009","article-title":"Alpha-2 agonists for attention-deficit\/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy","volume":"53","author":"Hirota","year":"2014","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2020.09.023_bib41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1089\/cap.2012.0093","article-title":"A\u00a0systematic review of combination therapy with stimulants and atomoxetine for attention-deficit\/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability","volume":"23","author":"Treuer","year":"2013","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"6","key":"10.1016\/j.jaac.2020.09.023_bib42","doi-asserted-by":"crossref","first-page":"e1562","DOI":"10.1542\/peds.2010-1360","article-title":"Treatment of maladaptive aggression in youth: CERT guidelines I. Engagement, assessment, and management","volume":"129","author":"Knapp","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2020.09.023_bib43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jaac.2015.09.020","article-title":"Access to psychosocial services prior to starting antipsychotic treatment among Medicaid-insured youth","volume":"55","author":"Finnerty","year":"2016","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2020.09.023_bib44","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-0352","article-title":"Parent-child interaction therapy: a meta-analysis","volume":"140","author":"Thomas","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2020.09.023_bib45","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1089\/cap.2015.0120","article-title":"Behavioral interventions for anger, irritability, and aggression in children and adolescents","volume":"26","author":"Sukhodolsky","year":"2016","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2020.09.023_bib46","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.chc.2015.02.007","article-title":"Multisystemic therapy for externalizing youth","volume":"24","author":"Zajac","year":"2015","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"10.1016\/j.jaac.2020.09.023_bib47","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s11920-013-0382-3","article-title":"Pharmacoepidemiology of antipsychotic use in youth with ADHD: trends and clinical implications","volume":"15","author":"Birnbaum","year":"2013","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.jaac.2020.09.023_bib48","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1176\/appi.ps.201400045","article-title":"Racial and ethnic differences in antipsychotic medication use among children enrolled in Medicaid","volume":"66","author":"Cataife","year":"2015","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.jaac.2020.09.023_bib49","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10597-009-9277-5","article-title":"Antidepressant and antipsychotic use and adherence among Medicaid youths: differences by race","volume":"46","author":"Sleath","year":"2010","journal-title":"Community Ment Health J"},{"key":"10.1016\/j.jaac.2020.09.023_bib50","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1176\/appi.ps.201900301","article-title":"Racial-ethnic differences in service use patterns among young, commercially insured individuals with recent-onset psychosis","volume":"71","author":"van der Ven","year":"2020","journal-title":"Psychiatr Serv"}],"container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856720319870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856720319870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T18:59:14Z","timestamp":1721415554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890856720319870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0890856720319870"],"URL":"https:\/\/doi.org\/10.1016\/j.jaac.2020.09.023","relation":{},"ISSN":["0890-8567"],"issn-type":[{"value":"0890-8567","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in Antipsychotic Medication Use in Young Privately Insured Children","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Child & Adolescent Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaac.2020.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a92020 American Academy of Child and Adolescent Psychiatry","name":"copyright","label":"Copyright"}]}}